Physician profile
Jason Compton
NPI 1205037363
$181,458.80
in general payments reported to CMS, 2019-2025
19 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $22.22 · 2021: $470 · 2022: $3,428 · 2023: $4,658 · 2024: $55K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $110K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $23K · Food and Beverage: $8,536 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $109,992.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,000.00 |
| Travel and Lodging | $23,309.36 |
| Food and Beverage | $8,535.99 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $169,265.44 | 2019-2025 | Precision7, Total30, Dailies Total1 |
| Coopervision INC. | $6,612.82 | 2021-2025 | Misight Contact Lens, Onefit Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $2,660.52 | 2022-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $1,404.00 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $421.28 | 2024-2025 | Xdemvy |
| Topcon Healthcare, INC. | $394.94 | 2024 | |
| Allergan, INC. | $139.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2024 | |
| Dompe US, INC. | $123.89 | 2022 | |
| Abbvie INC. | $70.53 | 2022 | |
| Carl Zeiss Meditec, INC. | $66.53 | 2023-2024 | Cirrus Hd-Oct |
| Glaukos Corporation | $45.88 | 2024 | Ce-Marked Kxla System |
| Sunovion Pharmaceuticals INC. | $27.77 | 2022 | |
| Harrow Eye, LLC | $27.17 | 2025 | Vevye |
| Sight Sciences, INC. | $22.22 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.46 | 2019 | |
| Horizon Therapeutics Plc | $17.33 | 2023 | Tepezza |
| Visioneering Technologies, INC. | $15.07 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.